Neutrophil extracellular traps-associated markers in malignant neoplasms of the female reproductive system after surgical treatment and adjuvant chemotherapy

Introduction. Studies evidence about a relation between increased circulating free DNA (cfDNA) concentrations and chemotherapy, the majority of which have been focused on considering a tumor as a source of cfDNA. It has been suggested that neutrophils also contribute to this process, as cancer-related cfDNA characteristics resemble those of neutrophil extracellular traps (NETs). Therefore, the elevated concentration of cfDNA observed in chemotherapy patients may be associated with NETosis.

Aim: assessment of NETosis markers in surgical treatment and adjuvant chemotherapy of patients with malignant neoplasms of the female reproductive system.

Materials and Methods. A prospective non-randomized interventional controlled study was carried out by enrolling 111 patients with malignant breast diseases and female genital organs of various localizations and stages hospitalized for elective surgical treatment or chemotherapy course. The control group included 33 healthy women. 69 patients underwent surgical treatment. Adjuvant chemotherapy with paclitaxel and carboplatin was performed in 25 patients with ovarian cancer and 17 patients with breast cancer. In cancer patients, citrullinated histone H3 (citH3) and myeloperoxidase (MPO) were chosen as NETosis biomarkers allowing to distinguish NETs from other tumor-derived cfDNA thereby improving quality of research study. The concentration of NETosis markers was assessed before surgery or onset of chemotherapy upon admission to hospital and 14 days after surgery or 14 days after the second course of chemotherapy.

Results. In all patients, the concentrations of NETosis markers before the start of therapy were significantly increased compared to the control group as well as 14 days after surgical treatment and 14 days after the second course of chemotherapy. However, in surgical patients, no significantly increased concentration of NETosis markers postvs. pre-surgery magnitude was observed. Upon that, patients underwent 2 courses of chemotherapy vs. baseline level were found to have significantly elevated magnitude of NETosis markers.

Conclusion. The study revealed the relationship between administration of paclitaxel-containing chemotherapy in patients with ovarian cancer and breast cancer and a rise in NETs level. Chemotherapy is an essential component for management of patients with malignant neoplasms of the female reproductive system, therefore, development of new strategies to lower a risk of thrombosis and resistance to it is of crucial importance.

1. van Es N., Sturk A., Middeldorp S., Nieuwland R. Effects of cancer on platelets. Semin Oncol. 2014;41(3):311–8. https://doi.org/10.1053/j.seminoncol.2014.04.015.

2. Thaler J., Pabinger I., Sperr W.R., Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014;133(3):303–5. https://doi.org/10.1016/j.thromres.2013.12.029.

3. Swystun L.L., Mukherjee S., Liaw P.C. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011;9(11):2313–21. https://doi.org/10.1111/j.1538-7836.2011.04465.x.

4. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37. https://doi.org/10.1038/nrc3066.

5. Lee Y.J., Yoon K.-A., Han J.-Y. et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy circulating DNA in prognosis of advanced NSCLC. Clin Cancer Res. 2011;17(15):5179–87. https://doi.org/10.1158/1078-0432.CCR-11-0400.

6. Demers M., Krause D.S., Schatzberg D. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancerassociated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076– 81. https://doi.org/10.1073/pnas.1200419109.

7. Cools-Lartigue J., Spicer J., Najmeh S., Ferri L. Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci. 2014;71(21):4179–94. https://doi.org/10.1007/s00018-014-1683-3.

8. Holdenrieder S., Stieber P., von Pawel J. et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non–small cell lung cancer. Clin Cancer Res. 2004;10(18 Pt):5981–7. https://doi.org/10.1158/1078-0432.CCR-04-0625.

9. Fuchs T.A., Kremer Hovinga J.A., Schatzberg D. et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120(6):1157–64. https://doi.org/10.1182/blood-2012-02-412197.

10. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.

11. Gonzalez H., Hagerling C., Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19– 20):1267–84. https://doi.org/10.1101/gad.314617.118.

12. Shaul M.E., Fridlender Z.G. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601–20. https://doi.org/10.1038/s41571-019-0222-4.

13. Burn G.L., Foti A., Marsman G. et al. The neutrophil. Immunity. 2021;54(7):1377–91. https://doi.org/10.1016/j.immuni.2021.06.006.

14. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134. https://doi.org/10.1038/nri.2017.105.

15. Huang H., Zhang H., Onuma A.E., Tsung A. Neutrophil elastase and neutrophil extracellular traps in the tumor microenvironment. Adv Exp Med Biol. 2020;1263:13–23. https://doi.org/10.1007/978-3-030-44518-8_2.

16. Garley M., Jabłońska E., Dąbrowska D. NETs in cancer. Tumor Biol. 2016;37(11):14355–61. https://doi.org/10.1007/s13277-016-5328-z.

17. Bianchi M., Niemiec M.J., Siler U. et al. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol. 2011;127(5):1243–52.e7. https://doi.org/10.1016/j.jaci.2011.01.021.

18. Wang S., Li Y., Xing C. et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res. 2020;10(7):1937–53.

19. Hedrick C.C., Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173–87. https://doi.org/10.1038/s41577-021-00571-6.

20. Kan M., Imaoka H., Watanabe K. et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol. 2020;86(2):203–10. https://doi.org/10.1007/s00280-020-04110-3.

21. Kasi P.M., Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78(7):737–45. https://doi.org/10.1007/s40265-018-0909-3

22. Zhang Y., Guoqiang L., Sun M., Lu X. Targeting and exploitation of tumorassociated neutrophils to enhance immunotherapy and drug delivery for cancer treatment. Cancer Biol Med. 2020;17(1):32–43. https://doi.org/10.20892/j.issn.2095-3941.2019.0372.

23. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003;25(11):1106–18. https://doi.org/10.1002/bies.10357.

24. Hensen S.M., Pruijn G.J. Methods for the detection of peptidylarginine deiminase (PAD) activity and protein citrullination. Mol Cel Proteomics. 2014;13(2):388–96. https://doi.org/10.1074/mcp.R113.033746.

25. van Beers J.J., Zendman A.J., Raijmakers R. et al. Peptidylarginine deiminase expression and activity in PAD2 knock-out and PAD4-low mice. Biochimie. 2013;95(2):299–308. https://doi.org/10.1016/j.biochi.2012.09.029.

26. Lewis H.D., Liddle J., Coote J.E. et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015;11(3):189–91. https://doi.org/10.1038/nchembio.1735.

27. Martinod K., Demers M., Fuchs T.A. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013;110(21):8674–9. https://doi.org/10.1073/pnas.1301059110.

28. Lysov Z., Dwivedi D.J., Gould T.J., Liaw P.C. Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA. Blood Coagul Fibrinolysis. 2017;28(1):72–82. https://doi.org/10.1097/MBC.0000000000000546.

29. Lysov Z., Swystun L.L., Kuruvilla S. et al. Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerasedependent tissue factor decryption. Blood Coagul Fibrinolysis. 2015;26(1):36–45. https://doi.org/10.1097/MBC.0000000000000145.

30. Wang H.-J., Huang H., Chuang Y.-C., Huang H.-C. Paclitaxel induces up-regulation of tissue factor in human aortic endothelial cells. Int Immunopharmacol. 2009;9(1):144–7. https://doi.org/10.1016/j.intimp.2008.10.003.

31. Hakkim A., Fürnrohr B.G., Amann K. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107(21):9813–18. https://doi.org/10.1073/pnas.0909927107.

32. Farrera C., Fadeel B. Macrophage clearance of neutrophil extracellular traps is a silent process. J Immunol. 2013;191(5):2647–56. https://doi.org/10.4049/jimmunol.1300436

33. Stoetzer O.J., Fersching D.M., Salat C. et al. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Lett. 2013;336(1):140–8. https://doi.org/10.1016/j.canlet.2013.04.013.

34. Longstaff C., Varjú I., Sótonyi P. et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem. 2013;288(10):6946–56. https://doi.org/10.1074/jbc.M112.404301.

35. Varjú I., Longstaff C., Szabó L. et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost. 2015;113(6):1289–98. https://doi.org/10.1160/TH14-08-0669.

36. Fuchs T.A., Brill A., Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880–5. https://doi.org/10.1073/pnas.1005743107.

37. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277(5698):665–7. https://doi.org/10.1038/277665a0.

38. Nogales E., Grayer Wolf S., Khan I.A. et al. Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature. 1995;375(6530):424–7. https://doi.org/10.1038/375424a0.

39. Nogales E. Structural insights into microtubule function. Annu Rev Biochem. 2000;69:277–302. https://doi.org/10.1146/annurev.biochem.69.1.277.

40. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77(3):1561–5. https://doi.org/10.1073/pnas.77.3.1561.

41. Marupudi N.I., Han J.E., Li K.W. et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6(5):609–21. https://doi.org/10.1517/14740338.6.5.609.

42. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res.1986;46(4 Pt):1972–9.

43. Zhang Y., Chandra V., Riquelme Sanchez E. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med. 2020;217(12):e20190354. https://doi.org/10.1084/jem.20190354.

44. Teijeira Á., Garasa S., Gato M. et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856– 71.e8. https://doi.org/10.1016/j.immuni.2020.03.001.

45. Zhu T., Zou X., Yang C. et al. Neutrophil extracellular traps promote gastric cancer metastasis by inducing epithelial-mesenchymal transition. Int J Mol Med. 2021;48(1):127. https://doi.org/10.3892/ijmm.2021.4960.

46. Ribatti D., Tamma R., Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Trans Oncol. 2020;13(6):100773. https://doi.org/10.1016/j.tranon.2020.100773.

47. Cabral-Pacheco G.A., Garza-Veloz I., Castruita-De la Rosa C. et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739. https://doi.org/10.3390/ijms21249739.

48. Gao H., Lan X., Li S., Xue Y. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. Tumor Biol. 2017;39(5):1010428317698368. https://doi.org/10.1177/1010428317698368.

49. Viallard C., Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409–26. https://doi.org/10.1007/s10456-017-9562-9.

50. Rayes R.F., Vourtzoumis P., Rjeily M.B. et al. Neutrophil extracellular trapassociated CEACAM1 as a putative therapeutic target to prevent metastatic progression of colon carcinoma. J Immunol. 2020;204:(8)2285–94. https://doi.org/10.4049/jimmunol.1900240.

51. Wherry E.J. T cell exhaustion. Nat Immunol. 2011;12(6):492–9. https://doi.org/10.1038/ni.2035.

52. Jiang W., He Y., He W. et al. Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 2021;11:622509. https://doi.org/10.3389/fimmu.2020.622509.

53. Kaltenmeier C., Yazdani H.O., Morder K. et al. Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment. Front Immunol. 2021;12:785222. https://doi.org/10.3389/fimmu.2021.785222.